Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?

Thyroid

Volumn 16, Issue 11, 2006, Pages 1113-1119

  Kohlfuerst, Susanne ^a   Igerc, Isabel ^a   Gallowitsch, Hans Juergen ^a   Gomez, Iris ^a   Kresnik, Ewald ^a   Matschnig, Sabine ^a   Lind, Peter ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DEPREOTIDE TC 99M; FLUORODEOXYGLUCOSE F 18; IODINE 131; IODIXANOL; IODIXANOL 270; LONG ACTING DRUG; OCTREOTIDE; SOMATOSTATIN RECEPTOR; THYROGLOBULIN; VISAPAQUE;

ABDOMINAL PAIN; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES COLOR; FEMALE; FLATULENCE; HUMAN; INJECTION SITE PAIN; LOOSE FECES; MALE; METASTASIS; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SWELLING; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT DURATION; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME; VOMITING; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; CARCINOMA, PAPILLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT FAILURE;

EID: 33845253632     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.1113     Document Type: Article

References (28)

1. Denzler B, Reubi JC 1999 Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 185:188-198.
2. England RJA, Atkin SL 2002 Somatostatins and their role in thyroid cancer. Clin Otolaryngol 27:120-123.
3. Kath R, Hoffken K 2000 The significance of somatostatin analogs in the antiproliferative treatment of carcinomas. Rec Results Cancer Res 153:23-43.
4. Virgolini I, Pangerl T, Bischof C, Smith-Jones P, Peck-Radosavljevic M 1997 Somatostatin receptor subtype expression in human tissues: A prediction for diagnosis and treatment of cancer? Eur J Clin Invest 27:645-647.
5. Arnold R, Simon B, Wied M 2000 Treatment of neuroendocrine GEP tumours with sandostatin analogues. Digestion 62(Suppl 1):84-91.
6. Zerek-Melen G, Lewinsky A, Pawlikowski M, Sewerynek E, Kunert-Radek J 1987 Influence of somatostatin and epidermal growth factor (EGF) on the proliferation of follicular cells in the organ-cultured rat thyroid. Res Exp Med 187:415-421.
7. Tsuzaki S, Moses A 1990 Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL-5 cells. Endocrinology 126:3131-3138.
8. Gorgoulis V, Aninos D, Priftis C, Evagelopoulou C, Karameris A, Kanavaros P, Spandidos DA 1992 Expression of epidermal growth factor, transforming growth facor-alpha and epidermal growth factor receptors in thyroid tumors. In Vivo 6:291-296.
9. Haugen D, Akslen L, Varhaug J, Lillehaug J 1993 Demonstration of a TGF-alpha EGF-receptor autocrine loop and c myc protein overexpression in papillary thyroid carcinomas. Int J Cancer 55:37-43.
10. Ain K, Taylor K 1994 Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 78:1097-1102.
11. Ain K, Taylor K, Tofiq S, Venkataraman G 1997 Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 82:1857-1862.
12. England RJA, Bedford KJ, Uassai L, Atkin SL 2003 Somatostatin receptor expression in thyroid disease [abstract]. Endocrine 5 P269.
13. Ain KB 1998 Anaplastic thyroid carcinoma: Behavior, biology, and therapeutic approaches. Thyroid 8:715-726.
14. Robbins RJ, Hill RH, Wang Weiping, Macapinlac HH, Larson SM 2000 Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10:177-183.
15. Diez JJ, Iglesias P 2002 Somatostatin analogs in the treatment of medullary thyroid carcinoma. J Endocrinol Invest 25:773-778.
16. Zatelli MC, Uberti EC 2004 Somatostatin receptors: From the basic science to clinical approach. Digest Liver Dis 36(Suppl 1):86-92.
17. Haugen BR, Lin EC 2001 Isotope imaging fot metastatic thyroid cancer. Endocrinol Metab Clin North Am 30:469-492.
18. Gulec SA, Serafini AN, Sridhar KS, Peker KR, Gysta A, Goodwin W, Sfakianakis GN, Moffat FL 1998 Somatostatin receptor expression in Hurthle cell cancer of the thyroid. J Nucl Med 39:243-245.
19. Zlock DW, Greenspan FS, Clark OH, Higgins CB 1994 Octroetide therapy in Advanced thyroid cancer. Thyroid 4:427-431.
20. Hoelting T, Duh QY, Clark OH, Herfarth C 1996 Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J Clin Endocrinol Metab Jul 81:2638-2641.
21. Stokkel MP, Reigmann HI, Verkooijen RB, Smit JW 2003 Indium-111- Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131. J Cancer Res Clin Oncol 129:287-294.
22. Christian JA, Cook GJ, Harmer C 2003 Indium-111-labelled octreotide scintigraphy in the diagnosis management of non-iodine avid metastatic carcinoma of the thyroid. Br J Cancer 89:258-261.
23. Ahlman H, Tisell LE, Wangberg B, Fjalling M, Forssell-Aronsson E, Kolby L, Nilsson O The relevance of somatostatin receptors in thyroid neoplasia. Yale J Biol Med 70:523-533.
24. Krenning EP, Bakker WH, Kwekkeboom DJ 1997 Biodistribution of a new chelated somatostatin analogue, (In-111-DOTA-D-Phe-Tyr)-octreotide: Comparison with (In-111-DTPA-D-Phe)-octreotide in humans. J Nucl Med 38:103(A).
25. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR 1998 Ythrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417-418.
26. Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Füger B, Li SR, Angelberger P, Raderer M, Wogritsch S, Kurtaran A, Kletter K and Dudczak R 2001 Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octroetide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 12(Suppl 2):41-45.
27. Gorges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch 2001 Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer.Thyroid 11:647-659.
28. Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, Haldemann A, Mueller-Brand J 2001 Radiopeptide transmitted internal irradiation of non iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 22:673-678.